Peer-Reviewed Publications

    Development of a realistic human respiratory tract cast representing physiological thermal conditions

    Asgari, M.; Lucci, F.; Bialek, J.; Dunan, B.; Andreatta, G.; Smajda, R.; Lani, S.; Blondiaux, N.; Majeed, S.; Steiner, S.; Schaller, J.-P.; Frentzel, S.; Hoeng, J.; Kuczaj, A. K.
    Published
    Apr 30, 2019
    DOI
    10.1080/02786826.2019.1612839
    Link to publication
    Topic
    Summary

    Toxicological assessment of inhaled aerosols and their effects on respiratory tissue cells requires accurate measurements of particle delivery, properties, evolution, and deposition in the human respiratory tract. These measurements are affected by both anatomical features and physiological factors, such as thermal conditions in the respiratory system. We constructed a segmented cast model, based on a realistic geometry of the human respiratory tract, equipped with features to control the temperature of the air flow. We then evaluated the thermal equilibrium of the air flow through the cast using both experimental measurements and computational fluid dynamics modeling. Uniform temperature distribution in the cast shell was achieved using parallel connection of the cast segments to a thermal bath by flow splitter. Air temperature inside the cast was shown to require <1 min to equilibrate with the temperature of the cast during internal circulation of hot water. Air flow temperature was shown to equilibrate with the cast temperature in the mouth-throat region, and a uniform temperature distribution was achieved in the other segments, resembling the thermal conditions of respiratory flow in the human lung. We showed that the cast successfully represents the physiological thermal conditions of the human respiratory system.

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.